Almac Diagnostics discusses new biomarker service

By Gareth Macdonald

- Last updated on GMT

Related tags: Pharmacology

Almac Diagnostics discusses new biomarker service
Almac says an effective biomarker strategy boosts a drug candidates’ chance of success and can ultimately add value to a developer’s business by opening door to diagnostics.

Earlier this month Almac’s diagnostics arm launched a new biomarker development service which, as VP of business development Michael Sloan told Outsourcing-pharma, is intended to cater for growing biopharmaceutical manufacturing sector demand.

Sloan explained that demand for pharmacodynamic biomarkers, as well as those for clinical trial enrichment, is increasing day by day as everyone from Big Pharma to biotech recognises their value in the drug development process.

He also suggested that, increasingly, such companies are adopting broader strategies involving commercial development of biomarkers for in clinic diagnostics purposes which, while a new market, is one in which he sees considerable growth potential.

Related news

Show more

Related products

show more

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Introduction to eLAS®

Introduction to eLAS®

Clinical Ink | 08-Mar-2021 | Product Brochure

Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus...

Related suppliers

Follow us

Products

View more

Webinars